{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:44:43Z","timestamp":1789562683462,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"DOI":"10.7759\/cureus.84703","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T01:47:09Z","timestamp":1748051229000},"source":"Crossref","is-referenced-by-count":4,"title":["Ravulizumab is Effective and Safe for Neuromyelitis Optica Spectrum Disorder Patients in Various Clinical Settings: A Single-Center Case Series with Concomitant Use of Rituximab"],"prefix":"10.7759","author":[{"given":"Ryota","family":"Amano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-023-01287-x","article-title":"A clinical approach to existing and emerging therapeutics in neuromyelitis optica spectrum disorder","volume":"23","author":"Yong HY","year":"2023","unstructured":"Yong HY, Burton JM. A clinical approach to existing and emerging therapeutics in neuromyelitis optica spectrum disorder. Curr Neurol Neurosci Rep. 2023, 23:489-506. 10.1007\/s11910-023-01287-x","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in myasthenia gravis: a review of the current evidence","volume":"19","author":"Vu T","year":"2023","unstructured":"Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr. Ravulizumab in myasthenia gravis: a review of the current evidence. Neuropsychiatr Dis Treat. 2023, 19:2639-55. 10.2147\/NDT.S374694","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock SJ","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al.. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023, 93:1053-68. 10.1002\/ana.26626","journal-title":"Ann Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00597-7","article-title":"Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder","volume":"13","author":"Clardy SL","year":"2024","unstructured":"Clardy SL, Pittock SJ, Aktas O, et al.. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurol Ther. 2024, 13:535-49. 10.1007\/s40120-024-00597-7","journal-title":"Neurol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e05899","article-title":"CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder","volume":"7","author":"Namatame C","year":"2021","unstructured":"Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M. CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. Heliyon. 2021, 7:e05899. 10.1016\/j.heliyon.2021.e05899","journal-title":"Heliyon"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112944","article-title":"Monitoring Ravulizumab effect on complement assays","volume":"490","author":"Willrich MA","year":"2021","unstructured":"Willrich MA, Ladwig PM, Martinez MA, Sridharan MR, Go RS, Murray DL. Monitoring Ravulizumab effect on complement assays. J Immunol Methods. 2021, 490:112944. 10.1016\/j.jim.2020.112944","journal-title":"J Immunol Methods"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122421","article-title":"Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab","volume":"134","author":"Cataland S","year":"2019","unstructured":"Cataland S, Ariceta G, Chen P, et al.. Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab. Blood. 2019, 134:1099. 10.1182\/blood-2019-122421","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura J","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S, et al.. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014, 370:632-9. 10.1056\/NEJMoa1311084","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12798","article-title":"The time course of complement blockage by ravulizumab in neuromyelitis optica spectrum disorder","volume":"12","author":"Amano R","year":"2024","unstructured":"Amano R. The time course of complement blockage by ravulizumab in neuromyelitis optica spectrum disorder. Neurol Clin Neurosci. 2024, 12:245-8. 10.1111\/ncn3.12798","journal-title":"Neurol Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras P","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, et al.. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022, 99:e2504-16. 10.1212\/WNL.0000000000201260","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00082-6","article-title":"Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial","volume":"11","author":"Annane D","year":"2023","unstructured":"Annane D, Pittock SJ, Kulkarni HS, et al.. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2023, 11:1051-63. 10.1016\/S2213-2600(23)00082-6","journal-title":"Lancet Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant M","year":"2015","unstructured":"Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015, 55:2398-403. 10.1111\/trf.13144","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.02.004","article-title":"C5a and pain development: An old molecule, a new target","volume":"112","author":"Quadros AU","year":"2016","unstructured":"Quadros AU, Cunha TM. C5a and pain development: An old molecule, a new target. Pharmacol Res. 2016, 112:58-67. 10.1016\/j.phrs.2016.02.004","journal-title":"Pharmacol Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.775","article-title":"Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum","volume":"71","author":"Guo Y","year":"2014","unstructured":"Guo Y, Lennon VA, Popescu BF, et al.. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol. 2014, 71:1025-9. 10.1001\/jamaneurol.2014.775","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019225","article-title":"Absence of aquaporin-4 in skeletal muscle alters proteins involved in bioenergetic pathways and calcium handling","volume":"6","author":"Basco D","year":"2011","unstructured":"Basco D, Nicchia GP, D'Alessandro A, Zolla L, Svelto M, Frigeri A. Absence of aquaporin-4 in skeletal muscle alters proteins involved in bioenergetic pathways and calcium handling. PLoS One. 2011, 6:e19225. 10.1371\/journal.pone.0019225","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100637R","article-title":"Neuromyelitis optica (NMO)-IgG-driven organelle reorganization in human iPSC-derived astrocytes","volume":"35","author":"Cho S","year":"2021","unstructured":"Cho S, Lee H, Jung M, et al.. Neuromyelitis optica (NMO)-IgG-driven organelle reorganization in human iPSC-derived astrocytes. FASEB J. 2021, 35:e21894. 10.1096\/fj.202100637R","journal-title":"FASEB J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1569","article-title":"Inebilizumab improves pain outcomes and quality of life in neuromyelitis optica spectrum disorder (P15-1.001)","volume":"98","author":"Kim HJ","year":"2022","unstructured":"Kim HJ, Smith M, Rees W, Gunsior M, Katz E, Paul F. Inebilizumab improves pain outcomes and quality of life in neuromyelitis optica spectrum disorder (P15-1.001). Neurology. 2022, 98:1569. 10.1212\/WNL.98.18_supplement.1569","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2024.06.12","article-title":"Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders","volume":"17","author":"Lou CY","year":"2024","unstructured":"Lou CY, Wang Y, Xing JY, Ma T, Tao L, Wang XT, Wang RS. Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders. Int J Ophthalmol. 2024, 17:1073-8. 10.18240\/ijo.2024.06.12","journal-title":"Int J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour R","year":"2015","unstructured":"Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al.. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015, 125:775-83. 10.1182\/blood-2014-03-560540","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365242-ravulizumab-is-effective-and-safe-for-neuromyelitis-optica-spectrum-disorder-patients-in-various-clinical-settings-a-single-center-case-series-with-concomitant-use-of-rituximab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T01:47:09Z","timestamp":1748051229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365242-ravulizumab-is-effective-and-safe-for-neuromyelitis-optica-spectrum-disorder-patients-in-various-clinical-settings-a-single-center-case-series-with-concomitant-use-of-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.84703","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}